Want to see HK:1244 full AI Analyst Report?
Top Page
3D Medicines, Inc.
(1244)
Select Model
Select Model
Rating:52Neutral
Price Target:
HK$2.50
▼(-59.28% Downside)
Action:Reiterated
Date:08/22/26
The score is primarily weighed down by weak financial performance (ongoing losses and negative free cash flow despite improving loss trends). Technicals are a notable offset, with the stock trading above major moving averages and positive momentum signals. Valuation is constrained by negative earnings and no indicated dividend yield.
Positive Factors
Very high gross margin
A very high gross margin indicates that approved products and commercialization activities can generate substantial value after direct costs. If maintained, this provides a strong base for funding research, development, and selling expenses as revenue stabilizes or product adoption expands.
Negative Factors
Contracting revenue
A sharp decline in revenue weakens operating leverage and makes it harder to absorb the substantial fixed costs associated with drug development and commercialization. Unless growth resumes, contraction can prolong losses, reduce reinvestment capacity, and undermine the scalability of the business model.
Read all positive and negative factors
Positive Factors
Negative Factors
Very high gross margin
A very high gross margin indicates that approved products and commercialization activities can generate substantial value after direct costs. If maintained, this provides a strong base for funding research, development, and selling expenses as revenue stabilizes or product adoption expands.
Read all positive factors
3D Medicines, Inc. (1244) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$627.37M
Dividend YieldN/A
Average Volume (3M)314.83K
Price to Earnings (P/E)―
Beta (1Y)1.37
Revenue Growth-17.22%
EPS Growth-6.13%
CountryHK
Employees162
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.72
Shares Outstanding258,177,000
10 Day Avg. Volume159,150
30 Day Avg. Volume314,833
Financial Highlights & Ratios
PEG Ratio1.66
Price to Book (P/B)1.97
Price to Sales (P/S)3.30
P/FCF Ratio-7.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
3D Medicines, Inc. Business Overview & Revenue Model
Company Description
Established in 2014 and headquartered in Qingdao, China, 3D Medicines Inc. is a biopharmaceutical company dedicated to the discovery, development, and market introduction of innovative oncology drugs and therapeutic candidates. Its core mission is...
3D Medicines, Inc. Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
54
Neutral
Cash Flow
32
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 356.09M | 445.65M | 634.95M | 567.39M | 60.26M |
| Gross Profit | 298.97M | 371.74M | 524.01M | 525.18M | 55.98M |
| EBITDA | -197.43M | -226.95M | -529.23M | -1.03B | -1.45B |
| Net Income | -177.53M | -182.66M | -524.70M | -1.02B | -1.43B |
Balance Sheet | |||||
| Total Assets | 936.64M | 1.22B | 1.43B | 1.33B | 1.06B |
| Cash, Cash Equivalents and Short-Term Investments | 438.10M | 840.98M | 996.58M | 942.03M | 824.48M |
| Total Debt | 152.85M | 237.62M | 282.43M | 175.70M | 3.15B |
| Total Liabilities | 391.54M | 512.54M | 558.20M | 436.65M | 3.33B |
| Stockholders Equity | 596.98M | 785.06M | 936.74M | 943.00M | -2.24B |
Cash Flow | |||||
| Free Cash Flow | -149.87M | -249.60M | -150.74M | -332.76M | -433.46M |
| Operating Cash Flow | -149.85M | -210.58M | -144.41M | -278.78M | -377.08M |
| Investing Cash Flow | -26.20M | 17.95M | -187.58M | -242.11M | -98.87M |
| Financing Cash Flow | -89.56M | -33.92M | 304.51M | 408.41M | 840.08M |
3D Medicines, Inc. Technical Analysis
Negative
6.14
Price Trends
2.35
Positive
2.78
Negative
3.70
Negative
Market Momentum
0.03
Positive
48.40
Neutral
20.36
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1244, the sentiment is Negative. The current price of 6.14 is above the 20-day moving average (MA) of 2.50, above the 50-day MA of 2.35, and above the 200-day MA of 3.70, indicating a neutral trend. The MACD of 0.03 indicates Positive momentum. The RSI at 48.40 is Neutral, neither overbought nor oversold. The STOCH value of 20.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1244.
3D Medicines, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | HK$627.37M | -2.78 | -30.93% | ― | -17.22% | -6.13% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | HK$864.79M | -2.14 | -66.16% | ― | 67.48% | 43.84% | |
46 Neutral | HK$8.10B | -42.05 | -10.27% | ― | -31.77% | -177.01% | |
45 Neutral | HK$436.45M | -1.75 | -32.08% | ― | 215.14% | 40.49% | |
44 Neutral | HK$7.96B | -71.58 | -9.49% | ― | 68.12% | 81.84% | |
42 Neutral | HK$432.37M | -4.42 | 133.13% | ― | -100.00% | 30.94% |
* Healthcare Sector Average
HK:1244
3D Medicines, Inc.
2.31
-7.16
-75.63%
HK:9966
Alphamab Oncology
8.45
-2.41
-22.19%
HK:2126
JW (Cayman) Therapeutics Co. Ltd.
2.00
-3.13
-61.01%
HK:2171
CARsgen Therapeutics Holdings Ltd.
13.43
-7.31
-35.25%
HK:2257
Sirnaomics Ltd.
3.78
-15.42
-80.31%
HK:6628
Transcenta Holding Limited
0.98
-4.72
-82.81%
3D Medicines, Inc. Corporate Events
3D Medicines Boosts Envafolimab Sales and Deepens Oncology Pipeline in H1 2026
Aug 31, 2026
3D Medicines reported interim unaudited results for the six months to June 30, 2026, highlighting steady commercial progress and pipeline advancement. Envafolimab generated RMB210.5 million in sales in China, up 0.6% year-on-year and 43% sequentia...
3D Medicines Fully Enforces Arbitration Win Against SELLAS as Key Trial Nears Endpoint
Aug 18, 2026
3D Medicines Inc. has secured full payment of HK$7,983,004.42 from SELLAS Life Sciences Group Inc., following an arbitral tribunal’s dismissal of all claims brought by SELLAS in a licence‑related dispute and its order that SELLAS bear ...
3D Medicines Sets Board Meeting to Approve Interim Results and Consider Dividend
Aug 17, 2026
3D Medicines Inc., a Cayman Islands–incorporated biopharmaceutical firm listed in Hong Kong, develops and commercializes innovative healthcare products through its subsidiaries. The group’s governance is overseen by a diversified board...
3D Medicines Revamps Board as Finance Veteran Joins After Non-Executive Director Steps Down
Aug 7, 2026
3D Medicines Inc. has announced a board reshuffle, with non-executive director Mr. Zhu Jinqiao set to retire on August 7, 2026, to focus on other professional commitments. The company emphasized that Mr. Zhu leaves without disagreement with the bo...
3D Medicines Details Board and Committee Structure
Aug 7, 2026
3D Medicines Inc. announced the current composition of its board of directors, listing one executive director, three non-executive directors and three independent non-executive directors. The company also detailed the structure of its audit, remun...
3D Medicines Updates Hong Kong Process Agent and Moves Principal Office
Aug 4, 2026
3D Medicines Inc. has appointed Ms. Leung Ching Ching as its new agent for the acceptance of service of process and notices in Hong Kong, replacing Ms. Li Ching Yi with effect from August 4, 2026. This change in process agent strengthens the compa...
3D Medicines Wins Arbitration Against SELLAS, Licence Deal Intact
Jul 27, 2026
3D Medicines Inc. has reported a favorable outcome in arbitration proceedings against SELLAS Life Sciences Group, Inc., with a Hong Kong International Arbitration Center tribunal dismissing all claims brought by SELLAS. The sole arbitrator ordered...
3D Medicines Shareholders Approve All AGM Resolutions, Expand Capital Mandates
Jun 30, 2026
Shareholders of 3D Medicines Inc. approved all resolutions at the company’s annual general meeting held in Beijing on June 30, 2026, including the adoption of the 2025 audited financial statements and the re-election of key board members. Th...
3D Medicines consolidates company secretary and authorised representative roles
Jun 30, 2026
3D Medicines Inc. has announced that the Hong Kong Stock Exchange has confirmed current joint company secretary Xia Fang as fully qualified to serve as company secretary under the relevant listing rules, ending a prior waiver period tied to her qu...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.